← Back to Search

Transcatheter Valve

Heterotopic Valve Implantation for Tricuspid Regurgitation (HOVER Trial)

Phase 3
Waitlist Available
Led By Brian P O'Neill, MD
Research Sponsored by Temple University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days, 6 months, annually to 5 years
Awards & highlights

HOVER Trial Summary

This trial is testing a new heart valve that can be implanted without open heart surgery. The goal is to see if it is safe and effective in people who are at high risk for complications from traditional surgery.

Eligible Conditions
  • Tricuspid Regurgitation

HOVER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days, 6 months, annually to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days, 6 months, annually to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Individual patient success
Procedural success
Secondary outcome measures
Acute kidney injury
EORTC QLQ-C30
ESAS-AM
+5 more

HOVER Trial Design

1Treatment groups
Experimental Treatment
Group I: Severe Tricuspid RegurgitationExperimental Treatment1 Intervention
This is a non-blinded (open label), non-randomized safety and feasibility study of the heterotopic implantation of the Edwards Sapien 3 valve.

Find a Location

Who is running the clinical trial?

Temple UniversityLead Sponsor
296 Previous Clinical Trials
82,789 Total Patients Enrolled
Henry Ford Health SystemLead Sponsor
300 Previous Clinical Trials
2,099,993 Total Patients Enrolled
Brian P O'Neill, MDPrincipal InvestigatorHenry Ford Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
2015. "Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02339974.
All > Tricuspid Regurgitation
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top